TY - JOUR
T1 - Chirurgie des sarcomes rétropéritonéaux
AU - Bonvalot, S.
AU - Vanel, D.
AU - Le Cesne, A.
AU - Terrier, P.
AU - Le Péchoux, C.
PY - 2006/2
Y1 - 2006/2
N2 - Retroperitoneal sarcomas comprise approximately 15% of all soft tissue sarcomas and 50% of all retroperitoneal tumours. Helical CT of the abdomen and pelvis, with selective use of MRI will establish the extent of the tumour, its retroperitoneal location, the degree of necrosis, and the evidence of metastasis. A CT guided core needle biopsy is the optimal pre operative tissue sampling. A complete surgical resection is the mainstay of the treatment with a rim of normal tissue that often requires removal of adjacent organs. The 5-year probability of local control is approximately 50%. The role of adjuvant therapy is evolving and at present should not be used outside the investigational setting.
AB - Retroperitoneal sarcomas comprise approximately 15% of all soft tissue sarcomas and 50% of all retroperitoneal tumours. Helical CT of the abdomen and pelvis, with selective use of MRI will establish the extent of the tumour, its retroperitoneal location, the degree of necrosis, and the evidence of metastasis. A CT guided core needle biopsy is the optimal pre operative tissue sampling. A complete surgical resection is the mainstay of the treatment with a rim of normal tissue that often requires removal of adjacent organs. The 5-year probability of local control is approximately 50%. The role of adjuvant therapy is evolving and at present should not be used outside the investigational setting.
KW - Retroperitoneal sarcomas
KW - Surgery
UR - http://www.scopus.com/inward/record.url?scp=33645321174&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33645321174&partnerID=8YFLogxK
U2 - 10.1016/j.canrad.2005.09.028
DO - 10.1016/j.canrad.2005.09.028
M3 - Articolo
C2 - 16300983
AN - SCOPUS:33645321174
VL - 10
SP - 41
EP - 49
JO - Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
JF - Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
SN - 1278-3218
IS - 1-2
ER -